Drug Profile
AB 1002
Alternative Names: AAV2i8.I-1c; AB-1002; BNP116.sc-CMV.I1c; Carfostin™; NAN-101Latest Information Update: 16 Nov 2023
Price :
$50
*
At a glance
- Originator Asklepios BioPharmaceutical; NanoCor Therapeutics
- Developer Asklepios BioPharmaceutical
- Class Gene therapies; Heart failure therapies
- Mechanism of Action Gene transference; Protein phosphatase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Heart failure
Most Recent Events
- 12 Nov 2023 Efficacy and adverse event data from a phase I trial in Heart failure released by Asklepios Biopharmaceuticals
- 11 Nov 2023 Asklepios Biopharmaceutical completes enrolment in its phase I trial in Heart failure (Treatment-experienced) in USA (Intracoronary) (NCT04179643)
- 20 Oct 2023 Phase-II clinical trials in Heart failure (Treatment-experienced) in USA (Intracoronary) (NCT05598333)